{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:11:11Z","timestamp":1769922671370,"version":"3.49.0"},"reference-count":95,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["16-0020"],"award-info":[{"award-number":["16-0020"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["1\/0090\/20"],"award-info":[{"award-number":["1\/0090\/20"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["1\/0549\/19"],"award-info":[{"award-number":["1\/0549\/19"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Agency of Slovak Ministry of Education, Science and Sports (VEGA)","award":["16-0020"],"award-info":[{"award-number":["16-0020"]}]},{"name":"Research Agency of Slovak Ministry of Education, Science and Sports (VEGA)","award":["1\/0090\/20"],"award-info":[{"award-number":["1\/0090\/20"]}]},{"name":"Research Agency of Slovak Ministry of Education, Science and Sports (VEGA)","award":["1\/0549\/19"],"award-info":[{"award-number":["1\/0549\/19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who do not respond optimally to novel ADP receptor blocker therapy, and this nonoptimal response (so-called \u201chigh on-treatment platelet reactivity\u201d or \u201cresistance\u201d) could be connected with increased risk of adverse ischemic events, such as myocardial re-infarction, target lesion failure and stent thrombosis. In addition, several risk factors have been proposed as factors associated with the phenomenon of inadequate response on novel ADPRB. These include obesity, multivessel coronary artery disease, high pre-treatment platelet reactivity and impaired metabolic status for prasugrel, as well as elderly, concomitant therapy with beta-blockers, morphine and platelet count for ticagrelor. There is no literature report describing nonoptimal therapeutic response on cangrelor, and cangrelor therapy seems to be a possible approach for overcoming HTPR on prasugrel and ticagrelor. However, the optimal therapeutic management of \u201cresistance\u201d on novel ADPRB is not clear and this issue requires further research. This narrative review article discusses the phenomenon of high on-treatment platelet reactivity on novel ADPRB, its importance in clinical practice and approaches for its therapeutic overcoming.<\/jats:p>","DOI":"10.3390\/jcm11237211","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T06:29:09Z","timestamp":1670221749000},"page":"7211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?"],"prefix":"10.3390","volume":"11","author":[{"given":"Peter","family":"Bla\u0161ko","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"},{"name":"Out-Patient Clinic of Cardiology, 957 01 Banovce nad Bebravou, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5561-2560","authenticated-orcid":false,"given":"Matej","family":"Samo\u0161","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Bolek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Stan\u010diakov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"\u0160kor\u0148ov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Jozef","family":"P\u00e9\u010d","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Jurica","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-0269","authenticated-orcid":false,"given":"J\u00e1n","family":"Sta\u0161ko","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e1n","family":"Mok\u00e1\u0148","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MBC.0000000000000406","article-title":"Ticagrelor: A safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?","volume":"27","author":"Fedor","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/09537104.2013.852659","article-title":"First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor","volume":"25","author":"Fiore","year":"2013","journal-title":"Platelets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2048872614534563","article-title":"Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment","volume":"4","author":"Musallam","year":"2014","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vph.2016.05.010","article-title":"Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors","volume":"84","author":"Thomas","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"ref_9","first-page":"40","article-title":"Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes","volume":"65","author":"Spiewak","year":"2007","journal-title":"Kardiol. Pol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/11539580-000000000-00000","article-title":"Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents","volume":"10","author":"Wang","year":"2010","journal-title":"Drugs R D"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4244\/EIJV9I3A53","article-title":"The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: Outcomes in patients with acute coronary syndrome after drug-eluting stent implantation","volume":"9","author":"Liang","year":"2013","journal-title":"EuroIntervention"},{"key":"ref_12","first-page":"962","article-title":"Impact of clopidogrel response on the clinical evolution in patients with acute coronary syndromes","volume":"116","author":"Costache","year":"2012","journal-title":"Rev. Med. Chir. Soc. Med. Nat. IASI"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e6553","DOI":"10.1097\/MD.0000000000006553","article-title":"Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"ref_14","first-page":"348","article-title":"Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management","volume":"61","author":"Guha","year":"2010","journal-title":"Indian Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ajem.2014.01.006","article-title":"Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis","volume":"32","author":"Duraj","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/clc.9","article-title":"A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance","volume":"30","author":"Lee","year":"2007","journal-title":"Clin. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1160\/TH07-01-0032","article-title":"Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function?","volume":"97","author":"Bonz","year":"2007","journal-title":"Thromb Haemost"},{"key":"ref_18","first-page":"E13","article-title":"Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance","volume":"23","author":"Jung","year":"2011","journal-title":"J. Invasive Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.14503\/THIJ-14-4491","article-title":"Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder","volume":"42","author":"Kim","year":"2015","journal-title":"Tex. Heart Inst. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.amjcard.2017.06.019","article-title":"Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study)","volume":"120","author":"Redfors","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00228-017-2271-x","article-title":"Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention","volume":"73","author":"Safranow","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/09537104.2015.1083969","article-title":"Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low-risk cohort","volume":"27","author":"Bolliger","year":"2015","journal-title":"Platelets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2018.07.020","article-title":"Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents","volume":"205","author":"Chung","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.amjcard.2019.07.054","article-title":"Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization","volume":"124","author":"Redfors","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","article-title":"Predictors of stent thrombosis and their implications for clinical practice","volume":"16","author":"Gori","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11239-016-1357-0","article-title":"Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: Results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition study","volume":"42","author":"Chandrasekhar","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/09537104.2017.1349306","article-title":"Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: A meta-analysis of randomized controlled trials","volume":"29","author":"Xing","year":"2017","journal-title":"Platelets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029614564208","article-title":"Efficacy of Change to New P2Y12 Receptor Antagonists in Patients High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention","volume":"21","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated with Ischemia and Bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/1076029614540036","article-title":"Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay","volume":"21","author":"Fedor","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00686","DOI":"10.1002\/prp2.686","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy","volume":"8","author":"Alvitigala","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.07.012","article-title":"Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100\u00ae and VerifyNow\u00ae","volume":"22","author":"Kinsella","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09537104.2010.543710","article-title":"Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin","volume":"22","author":"Crescente","year":"2011","journal-title":"Platelets"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/09537104.2010.514967","article-title":"The new INNOVANCE\u00ae PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition","volume":"22","author":"Koessler","year":"2011","journal-title":"Platelets"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1309\/0G1PEJ00J8KP8357","article-title":"Comparison of Different Methods to Evaluate the Effect of Aspirin on Platelet Function in High-Risk Patients with Ischemic Heart Disease Receiving Dual Antiplatelet Treatment","volume":"128","author":"Paniccia","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3343\/alm.2019.39.1.23","article-title":"Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction","volume":"39","author":"Kweon","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"ref_38","first-page":"409","article-title":"A study of platelet aggregation in patients with acute myocardial infarction at presentation and after 48 hrs of initiating standard anti platelet therapy","volume":"63","author":"Guha","year":"2013","journal-title":"Indian Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2174\/1381612822666151208120106","article-title":"Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor","volume":"22","author":"Dobesh","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1536\/ihj.20-309","article-title":"Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis","volume":"62","author":"Wang","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.cjca.2021.03.017","article-title":"Successful Therapy with Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance","volume":"37","author":"Lee","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-015-0445-3","article-title":"Cangrelor: A Review in Percutaneous Coronary Intervention","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.carrev.2019.04.018","article-title":"Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention","volume":"20","author":"Chen","year":"2019","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High On-Treatment Platelet Reactivity after Prasugrel Loading Dose and Cardiovascular Events after Percutaneous Coronary Intervention in Acute Coronary Syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2478\/acm-2018-0011","article-title":"On-treatment platelet reactivity in the era of new ADP receptor blockers: Data from a real-world clinical practice","volume":"18","author":"Bolek","year":"2018","journal-title":"Acta Med. Martiniana"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH11-09-0622","article-title":"Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel","volume":"107","author":"Kuliczkowski","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2012.08.043","article-title":"Prasugrel Monitoring and Bleeding in Real World Patients","volume":"111","author":"Cayla","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/09537104.2014.959914","article-title":"Comparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarction patients: The COMPASSION study","volume":"26","author":"Laine","year":"2015","journal-title":"Platelets"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: A systematic review and meta-analysis","volume":"13","author":"Lemesle","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_51","first-page":"373","article-title":"Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor","volume":"27","author":"Akca","year":"2015","journal-title":"Platelets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09537104.2018.1445836","article-title":"Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: A retrospective pharmacodynamic analysis","volume":"30","author":"Selhorst","year":"2018","journal-title":"Platelets"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jjcc.2018.10.005","article-title":"Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation","volume":"73","author":"Verdoia","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2459\/JCM.0000000000001222","article-title":"Ticagrelor and prasugrel in acute coronary syndrome: A single-arm crossover platelet reactivity study","volume":"22","author":"Verdoia","year":"2021","journal-title":"J. Cardiovasc. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/eurheartj\/ehz202","article-title":"Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: A pre-specified exploratory analysis from the TROPICAL-ACS trial","volume":"40","author":"Aradi","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-010-0533-x","article-title":"A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty","volume":"31","author":"Silvano","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jccase.2016.01.001","article-title":"Repetitive stent thrombosis in a patient who had resistance to both clopidogrel and prasugrel","volume":"13","author":"Ohno","year":"2016","journal-title":"J. Cardiol. Cases"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-019-0197-5","article-title":"A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease","volume":"17","author":"Warlo","year":"2019","journal-title":"Thromb. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with Diabetes","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.thromres.2013.04.030","article-title":"Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"132","author":"Laine","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome","volume":"111","author":"Laine","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11239-015-1279-2","article-title":"Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes","volume":"41","author":"Verdoia","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vph.2015.10.006","article-title":"Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor","volume":"79","author":"Barbieri","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"ref_66","first-page":"282","article-title":"Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients","volume":"13","author":"Li","year":"2016","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/jth.14592","article-title":"Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome","volume":"17","author":"Laine","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.vph.2015.04.014","article-title":"Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation","volume":"77","author":"Verdoia","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.numecd.2019.09.018","article-title":"Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor","volume":"30","author":"Verdoia","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs. prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events","volume":"112","author":"Stavrou","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ahj.2014.06.026","article-title":"Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis","volume":"168","author":"Alexopoulos","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjcard.2017.01.002","article-title":"Comparison of Platelet Reactivity in Black Versus White Patients with Acute Coronary Syndromes After Treatment with Ticagrelor","volume":"119","author":"Gaglia","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e005650","DOI":"10.1161\/JAHA.117.005650","article-title":"Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention","volume":"6","author":"Sweeny","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cjca.2017.09.002","article-title":"Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients with Non-ST-Elevation Acute Coronary Syndrome Undergoing","volume":"33","author":"Liu","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wen, M., Li, Y., Qu, X., Zhu, Y., Tian, L., Shen, Z., Yang, X., and Shi, X. (2020). Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: A meta-analysis. BMC Cardiovasc. Disord., 20.","DOI":"10.1186\/s12872-020-01603-0"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"905607","DOI":"10.3389\/fcvm.2022.905607","article-title":"Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients with Acute Coronary Syndrome: A Meta-Analysis","volume":"9","author":"Dai","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_77","first-page":"002719","article-title":"A Case of Ticagrelor Resistance","volume":"8","author":"Malik","year":"2021","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ihj.2017.10.012","article-title":"Sub-acute stent thrombosis secondary to ticagrelor resistance-Myth or reality!","volume":"69","author":"Jariwala","year":"2017","journal-title":"Indian Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2013.11.019","article-title":"Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients","volume":"7","author":"Rollini","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/09537104.2021.1983162","article-title":"\u201cTailored\u201d antiplatelet bridging therapy with cangrelor: Moving toward personalized medicine","volume":"33","author":"Valenti","year":"2021","journal-title":"Platelets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet Inhibition with Cangrelor and Crushed Ticagrelor in Patients with ST-Segment\u2013Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijcard.2012.09.214","article-title":"Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy","volume":"168","author":"Cuisset","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjcard.2013.09.011","article-title":"Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting","volume":"113","author":"Pankert","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/eurheartj\/ehr407","article-title":"High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study","volume":"33","author":"Silvain","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated with Prasugrel After Acute Coronary Syndrome","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.amjcard.2012.12.013","article-title":"Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications","volume":"111","author":"Grosdidier","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.2174\/13816128113199990002","article-title":"Factors Affecting Residual Platelet Aggregation in Prasugrel Treated Patients","volume":"19","author":"Alexopoulos","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_88","first-page":"2909436","article-title":"The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study","volume":"2016","author":"Fedor","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41598-019-40628-0","article-title":"Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor","volume":"9","author":"Adamski","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2459\/JCM.0000000000000981","article-title":"Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome","volume":"21","author":"Ilardi","year":"2020","journal-title":"J. Cardiovasc. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MJT.0000000000000454","article-title":"Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?\u2014A Pilot Prospective Study","volume":"24","author":"Bolek","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jcin.2012.10.007","article-title":"Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy","volume":"6","author":"Ferreiro","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.thromres.2013.05.029","article-title":"Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy","volume":"132","author":"Christ","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000353674","article-title":"Triple versus dual antiplatelet therapy in acute coronary syndromes: Adding cilostazol to aspirin and clopidogrel?","volume":"126","author":"Niazi","year":"2013","journal-title":"Cardiology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ijcard.2014.07.239","article-title":"Effectiveness of switching \u2018low responders\u2019 to prasugrel to ticagrelor after acute coronary syndrome","volume":"176","author":"Bassez","year":"2014","journal-title":"Int. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/7211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:33:55Z","timestamp":1760146435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/7211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":95,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11237211"],"URL":"https:\/\/doi.org\/10.3390\/jcm11237211","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]}}}